Tissue microarrays for high-throughput molecular profiling of tumor specimens

Many genes and signalling pathways controlling cell proliferation, death and differentiation, as well as genomic integrity, are involved in cancer development. New techniques, such as serial analysis of gene expression and cDNA microarrays, have enabled measurement of the expression of thousands of genes in a single experiment, revealing many new, potentially important cancer genes1,2. These genome screening tools can comprehensively survey one tumor at a time; however, analysis of hundreds of specimens from patients in different stages of disease is needed to establish the diagnostic, prognostic and therapeutic importance of each of the emerging cancer gene candidates. Here we have developed an array-based high-throughput technique that facilitates gene expression and copy number surveys of very large numbers of tumors. As many as 1000 cylindrical tissue biopsies from individual tumors can be distributed in a single tumor tissue microarray. Sections of the microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array, and consecutive sections allow the rapid analysis of hundreds of molecular markers in the same set of specimens. Our detection of six gene amplifications as well as p53 and estrogen receptor expression in breast cancer demonstrates the power of this technique for defining new subgroups of tumors.

[1]  H. Battifora The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[2]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[3]  H. Battifora,et al.  The checkerboard tissue block. An improved multitissue control block. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[4]  D. Allred,et al.  Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. , 1990, Archives of surgery.

[5]  M. Fernö,et al.  Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. , 1991, British Journal of Cancer.

[6]  D. Pinkel,et al.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Dutrillaux,et al.  Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique , 1994, Genes, chromosomes & cancer.

[8]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[9]  W. Kuo,et al.  Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. , 1994, Cancer research.

[10]  P. Meltzer,et al.  Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection , 1994, Nature Genetics.

[11]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[12]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[13]  Mybl2 (Bmyb) maps to mouse chromosome 2 and human chromosome 20q 13.1. , 1996, Genomics.

[14]  R. Zeillinger,et al.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.

[15]  Persons Dl,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .

[16]  O. Kallioniemi,et al.  Increased copy number at 17q22‐q24 by CGH in breast cancer is due to high‐level amplification of two separate regions , 1997, Genes, chromosomes & cancer.

[17]  A. Marchetti,et al.  Cyclin‐d1‐gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 immunohistochemical expression , 1997, International journal of cancer.

[18]  T. Ried Interphase cytogenetics and its role in molecular diagnostics of solid tumors. , 1998, The American journal of pathology.